Structural Diversity of Ligand-Binding Androgen Receptors Revealed by Microsecond Long Molecular Dynamics Simulations and Enhanced Sampling.
暂无分享,去创建一个
Dan Li | Tingjun Hou | Minghui Yang | Na Liu | Wenfang Zhou | Mojie Duan | Minghui Yang | Dan Li | Tingjun Hou | Na Liu | Mojie Duan | Wenfang Zhou
[1] Massimiliano Bonomi,et al. PLUMED 2: New feathers for an old bird , 2013, Comput. Phys. Commun..
[2] Hualiang Jiang,et al. Effects of HO-/MeO-PBDEs on androgen receptor: in vitro investigation and helix 12-involved MD simulation. , 2013, Environmental science & technology.
[3] David W. Johnson,et al. Molecular cell biology of androgen receptor signalling. , 2010, The international journal of biochemistry & cell biology.
[4] R. Vessella,et al. Androgen receptor splice variants determine taxane sensitivity in prostate cancer. , 2012, Cancer research.
[5] Isao Nakanishi,et al. Subtle Structural Changes in Tetrahydroquinolines, A New Class of Nonsteroidal Selective Androgen Receptor Modulators, Induce Different Functions , 2012, J. Chem. Inf. Model..
[6] G. Bubley,et al. Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[7] D. Tindall,et al. Mechanisms of androgen-refractory prostate cancer. , 2004, The New England journal of medicine.
[8] D. Osguthorpe,et al. Mechanism of androgen receptor antagonism by bicalutamide in the treatment of prostate cancer. , 2011, Biochemistry.
[9] Peter Scholz,et al. Structural Evidence for Ligand Specificity in the Binding Domain of the Human Androgen Receptor , 2000, The Journal of Biological Chemistry.
[10] Joshua M. Korn,et al. An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). , 2013, Cancer discovery.
[11] Duncan Poole,et al. Routine Microsecond Molecular Dynamics Simulations with AMBER on GPUs. 1. Generalized Born , 2012, Journal of chemical theory and computation.
[12] Jinming Zhou,et al. Study of the impact of the T877A mutation on ligand‐induced helix‐12 positioning of the androgen receptor resulted in design and synthesis of novel antiandrogens , 2010, Proteins.
[13] R. Fletterick,et al. The Molecular Mechanisms of Coactivator Utilization in Ligand-dependent Transactivation by the Androgen Receptor* , 2005, Journal of Biological Chemistry.
[14] Junmei Wang,et al. Development and testing of a general amber force field , 2004, J. Comput. Chem..
[15] H. Gronemeyer,et al. Activation Function 2 in the Human Androgen Receptor Ligand Binding Domain Mediates Interdomain Communication with the NH2-terminal Domain* , 1999, The Journal of Biological Chemistry.
[16] J. P. Grossman,et al. Biomolecular simulation: a computational microscope for molecular biology. , 2012, Annual review of biophysics.
[17] J. Persson,et al. Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer , 2013, Drug design, development and therapy.
[18] Ross C. Walker,et al. An overview of the Amber biomolecular simulation package , 2013 .
[19] S Gnanakaran,et al. Peptide folding simulations. , 2003, Current opinion in structural biology.
[20] P. Nelson,et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. , 2008, Cancer research.
[21] J. Ferlay,et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. , 2013, European journal of cancer.
[22] R. Dyer,et al. Fast events in protein folding: helix melting and formation in a small peptide. , 1996, Biochemistry.
[23] Raj Kumar,et al. Allosteric modulators of steroid hormone receptors: structural dynamics and gene regulation. , 2012, Endocrine reviews.
[24] H. Scher,et al. Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer , 2009, Science.
[25] Duane D. Miller,et al. Structural basis for antagonism and resistance of bicalutamide in prostate cancer , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[26] A. Laio,et al. A bias-exchange approach to protein folding. , 2007, The journal of physical chemistry. B.
[27] Jonathan Greer,et al. The Three-dimensional Structures of Antagonistic and Agonistic Forms of the Glucocorticoid Receptor Ligand-binding Domain , 2003, Journal of Biological Chemistry.
[28] Barry R. Goldspiel,et al. Flutamide: An Antiandrogen for Advanced Prostate Cancer , 1990, DICP : the annals of pharmacotherapy.
[29] R. Swendsen,et al. THE weighted histogram analysis method for free‐energy calculations on biomolecules. I. The method , 1992 .
[30] A. Laio,et al. Escaping free-energy minima , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[31] A. Sali,et al. Modeling of loops in protein structures , 2000, Protein science : a publication of the Protein Society.
[32] R. Fletterick,et al. A conserved surface on the ligand binding domain of nuclear receptors for allosteric control , 2012, Molecular and Cellular Endocrinology.
[33] J. Richardson,et al. The penultimate rotamer library , 2000, Proteins.
[34] Gerrit Groenhof,et al. GROMACS: Fast, flexible, and free , 2005, J. Comput. Chem..
[35] Duane D. Miller,et al. Structural Basis for Accommodation of Nonsteroidal Ligands in the Androgen Receptor* , 2005, Journal of Biological Chemistry.
[36] Solène Grosdidier,et al. Allosteric conversation in the androgen receptor ligand-binding domain surfaces. , 2012, Molecular endocrinology.
[37] Woody Sherman,et al. Exploring protein flexibility: incorporating structural ensembles from crystal structures and simulation into virtual screening protocols. , 2012, The journal of physical chemistry. B.
[38] Kenneth J. Pienta,et al. Mechanisms Underlying the Development of Androgen-Independent Prostate Cancer , 2006, Clinical Cancer Research.
[39] Alessandro Laio,et al. A Kinetic Model of Trp-Cage Folding from Multiple Biased Molecular Dynamics Simulations , 2009, PLoS Comput. Biol..
[40] J. Bono,et al. Novel drugs targeting the androgen receptor pathway in prostate cancer , 2014, Cancer and Metastasis Reviews.
[41] V. Arora,et al. Overcoming mutation-based resistance to antiandrogens with rational drug design , 2013, eLife.
[42] Xue Xu,et al. Dynamic communication between androgen and coactivator: Mutually induced conformational perturbations in androgen receptor ligand‐binding domain , 2011, Proteins.
[43] K Schulten,et al. VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.
[44] B. Brooks,et al. Langevin dynamics of peptides: The frictional dependence of isomerization rates of N‐acetylalanyl‐N′‐methylamide , 1992, Biopolymers.
[45] Claudio N. Cavasotto,et al. Molecular basis of agonicity and antagonicity in the androgen receptor studied by molecular dynamics simulations. , 2008, Journal of molecular graphics & modelling.
[46] Alessandro Laio,et al. METAGUI. A VMD interface for analyzing metadynamics and molecular dynamics simulations , 2012, Comput. Phys. Commun..
[47] Howard C. Shen,et al. Structural basis for nuclear receptor corepressor recruitment by antagonist-liganded androgen receptor , 2008, Molecular Cancer Therapeutics.
[48] N. McCarthy. Prostate cancer: Studying the classics , 2011, Nature Reviews Cancer.
[49] Alessandro Laio,et al. A VMD interface for analyzing metadynamics and molecular dynamics simulations ✩ , 2011 .
[50] Takahiro Matsumoto,et al. The androgen receptor in health and disease. , 2013, Annual review of physiology.
[51] H. Xu,et al. Androgen receptor: structure, role in prostate cancer and drug discovery , 2014, Acta Pharmacologica Sinica.
[52] Conrad C. Huang,et al. UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..
[53] E. Wilson,et al. Modulation of Androgen Receptor Activation Function 2 by Testosterone and Dihydrotestosterone* , 2007, Journal of Biological Chemistry.
[54] R. Dror,et al. Improved side-chain torsion potentials for the Amber ff99SB protein force field , 2010, Proteins.
[55] G. Blackledge,et al. Casodex (bicalutamide): overview of a new antiandrogen developed for the treatment of prostate cancer. , 1997, European Urology.
[56] T. Darden,et al. A smooth particle mesh Ewald method , 1995 .
[57] Ruben Abagyan,et al. Improved docking, screening and selectivity prediction for small molecule nuclear receptor modulators using conformational ensembles , 2010, J. Comput. Aided Mol. Des..
[58] C. Ryan,et al. Androgen Receptor Directed Therapies in Castration-Resistant Metastatic Prostate Cancer , 2012, Current Treatment Options in Oncology.
[59] Y. Shang,et al. Formation of the androgen receptor transcription complex. , 2002, Molecular cell.